Small Cap Wonder
Read why this microcap stock might stand out in the market.
Get the info now.

APS Insider Trading (Aptose Biosciences)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$0.00
Insider Selling (Last 12 Months): C$115,593.40

Aptose Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Aptose Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aptose Biosciences Share Price & Price History

Current Price: C$2.65
Price Change: Price Decrease of -0.05 (-1.85%)
As of 10/20/2021 01:00 AM ET

This chart shows the closing price history over time for APS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
pixel

Aptose Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/21/2021Warren WhiteheadDirectorSell15,400C$4.15C$63,848.4024,600
12/22/2020Warren WhiteheadDirectorSell10,000C$5.17C$51,745.0050,000
7/10/2020Gregory Kwok Lee ChowSenior OfficerSell126,668C$8.47C$1,072,877.96232,846
7/10/2020William Glenn RiceDirectorSell168,891C$8.47C$1,430,506.77297,523
6/23/2020Warren WhiteheadDirectorSell5,000C$9.69C$48,450.0058,000
10/24/2019William Glenn RiceDirectorBuy10,000C$2.53C$25,344.00163,014
4/18/2019William Glenn RiceDirectorBuy10,000C$2.44C$24,429.24153,014
3/14/2019William Glenn RiceDirectorBuy10,000C$2.51C$25,070.76143,014
See Full Table
Insider Selling at Aptose Biosciences?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Aptose Biosciences and related companies.

SEC Filings (Institutional Ownership Changes) for Aptose Biosciences (TSE:APS)

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Read More on Aptose Biosciences

Today's Range

Now: C$2.65
Low: C$2.62
High: C$2.73

50 Day Range

MA: C$3.26
Low: C$2.71
High: C$3.87

52 Week Range

Now: C$2.65
Low: C$2.62
High: C$9.40

Volume

53,222 shs

Average Volume

47,979 shs

Market Capitalization

C$235.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Aptose Biosciences?

Aptose Biosciences' top insider investors include:
  1. William Glenn Rice (Director)
  2. Gregory Kwok Lee Chow (Senior Officer)
  3. Warren Whitehead (Director)
Small Cap Wonder
Read why this microcap stock might stand out in the market.
Get the info now.